CurveBeam AI (ASX:CVB) Short-Term Debt: A$1.29 Mil (As of Dec. 2025)


What is CurveBeam AI Short-Term Debt?

CurveBeam AI ASX:CVB -5.56% Short-Term Debt is A$1.29 Mil as of Dec. 2025. The stock has 5 warning signs investors should review.

CurveBeam AI's Short-Term Debt for the quarter that ended in Dec. 2025 was A$1.29 Mil.

CurveBeam AI's quarterly Short-Term Debt increased from Dec. 2024 (A$0.96 Mil) to Jun. 2025 (A$1.49 Mil) but then declined from Jun. 2025 (A$1.49 Mil) to Dec. 2025 (A$1.29 Mil).

CurveBeam AI's annual Short-Term Debt increased from Jun. 2023 (A$1.07 Mil) to Jun. 2024 (A$1.10 Mil) and increased from Jun. 2024 (A$1.10 Mil) to Jun. 2025 (A$1.49 Mil).

CurveBeam AI Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

CurveBeam AI Short-Term Debt Related Terms

CurveBeam AI Short-Term Debt Historical Data

* Premium members only.

The historical data trend for CurveBeam AI's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CurveBeam AI Short-Term Debt Chart

CurveBeam AI Annual Data
Trend Jun21 Jun22 Jun23 Jun24 Jun25
Short-Term Debt
0.00 0.00 1.07 1.10 1.49

CurveBeam AI Semi-Annual Data
Jun21 Dec21 Jun22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Short-Term Debt Get a 7-Day Free Trial Premium Member Only 1.02 1.10 0.96 1.49 1.29
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of A$1.29 Mil mean?
CurveBeam AI (ASX:CVB) has a Short-Term Debt of A$1.29 Mil as of Dec. 2025.
Is CurveBeam AI's Short-Term Debt too high?
CurveBeam AI's current Short-Term Debt is A$1.29 Mil.
How does CurveBeam AI's Short-Term Debt compare to ABT and SYK?
CurveBeam AI's Short-Term Debt of A$1.29 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Medical Devices & Instruments company?
A good Short-Term Debt depends on the Medical Devices & Instruments industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. CurveBeam AI's current Short-Term Debt is A$1.29 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CurveBeam AI stock overvalued right now?
CurveBeam AI (ASX:CVB) has a current Short-Term Debt of A$1.29 Mil. The current Short-Term Debt is A$1.29 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For CurveBeam AI (ASX:CVB), the current Short-Term Debt is A$1.29 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CurveBeam AI Business Description

Address 10 Queen Street, Level 10, Melbourne, VIC, AUS, 3000
CurveBeam AI Ltd is a manufacturer of specialized imaging equipment that has developed software that, through the use of artificial intelligence (AI), and deep learning AI (DLAI), automates the scan processing and analysis of the high-quality images produced from the company's CT devices to assist in the clinical assessment. The company has one operating segment, being the research, design, manufacture and sale of cone beam CT imaging equipment for orthopaedic specialties, which includes the development, validation and preparation for commercialisation of a HRpQCT Medical Device and Software as a Service (SaaS) platform.